Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
16 December 2024 |
Main ID: |
EUCTR2021-000037-14-IT |
Date of registration:
|
26/11/2021 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A Global Phase 3 Double-Blind, Placebo-Controlled study to assess Efficacy and Safety of Birtamimab Plus Standard of Care vs. Placebo Plus Standard
of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
|
Scientific title:
|
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo
Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis - NA |
Date of first enrolment:
|
21/01/2022 |
Target sample size:
|
150 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000037-14 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no Number of treatment arms in the trial: 2
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Australia
|
Austria
|
Belgium
|
Brazil
|
Canada
|
Czech Republic
|
Czechia
|
Denmark
|
France
|
Germany
|
Greece
|
Hungary
|
Ireland
|
Israel
|
Italy
|
Korea, Republic of
|
Netherlands
|
Poland
|
Portugal
|
Spain
|
Taiwan
|
Turkey
|
United Kingdom
|
United States
|
Contacts
|
Name:
|
Regulatory Affairs
|
Address:
|
77 Sir John Rogerson's Quay, Block C
D02 T804
Grand Canal Docklands, Dublin 2
Ireland |
Telephone:
|
000000 |
Email:
|
regaffairs@prothena.com |
Affiliation:
|
Prothena Biosciences Limited |
|
Name:
|
Regulatory Affairs
|
Address:
|
77 Sir John Rogerson's Quay, Block C
D02 T804
Grand Canal Docklands, Dublin 2
Ireland |
Telephone:
|
000000 |
Email:
|
regaffairs@prothena.com |
Affiliation:
|
Prothena Biosciences Limited |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1.Aged =18 years 2.Newly diagnosed and AL amyloidosis treatment naive 3.Bone marrow demonstrating clonal plasma cells 4.Confirmed diagnosis of AL amyloidosis by the following: -Histochemical diagnosis of amyloidosis determined by polarizing light microscopy of green birefringent material in Congo red-stained tissue specimens OR characteristic electron microscopy appearance AND -Confirmatory immunohistochemistry OR mass spectroscopy of AL amyloidosis 5.Confirmed diagnosis of AL amyloidosis by mass spectrometry or immunoelectron microscopy of amyloid material in tissue biopsy if the subject meets any of the following: -Is black or African American -Is over 75 years of age with concurrent monoclonal gammopathy -Has a history of familial amyloidosis and has concurrent monoclonal gammopathy OR -If the subject meets any of the above 3 conditions and has echocardiographic evidence of amyloidosis, biopsy-proven amyloidosis with a monoclonal gammopathy and no tissue is available for mass spectrometry or immunoelectron microscopy, the subject must have gene sequencing consistent with transthyretin (TTR) wild type (e.g., no TTR mutation present) AND must score 0 in technetium-99m-3,3- diphosphono-1,2 propanodicarboxylic acid (99mTc DPD), hydroxymethylenediphosphonate (99mTc HMDP), or pyrophosphate (99mTc PYP) scintigraphy 6.Cardiac involvement as defined by all of the following: -Past documented or presently noted clinical signs and symptoms supportive of a diagnosis of heart failure in the setting of a confirmed diagnosis of AL amyloidosis in the absence of an alternative explanation for heart failure -Either an endomyocardial biopsy demonstrating AL amyloidosis or an echocardiogram demonstrating a mean left ventricular wall thickness at diastole >12 mm in the absence of other causes (e.g., severe hypertension, aortic stenosis), which would adequately explain the degree of wall thickening 7.Confirmed Mayo Stage IV as defined by: -NT-proBNP =1800 pg/mL and -Troponin-T >0.03 ng/mL and -dFLC =18 mg/dL 8.Planned first-line chemotherapy contains bortezomib administered subcutaneously weekly 9.Adequate bone marrow reserve, hepatic function, and renal function, as demonstrated by: -Absolute neutrophil count =1.0 × 10e9/L -Platelet count =75 × 10e9/L -Hemoglobin =9 g/dL -Total bilirubin = 2 × the upper limit of normal (ULN) -Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase =3 × ULN -Alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase =3 × ULN -Alkaline phosphatase (ALP) =5 × ULN (except for subjects with hepatomegaly and isozymes specific to liver, rather than bone) -Estimated glomerular filtration rate (eGFR) =30 mL/min/1.73 m2 as estimated by the Chronic Kidney Disease Epidemiology Collaboration equation 10.Seated systolic blood pressure (BP) 90 to 180 mmHg 11.Distance walked during each Screening 6MWT is >30 meters and <550 meters 12.Women of childbearing potential (WOCBP) must have 2 negative pregnancy tests during Screening, the second within 24 hours prior to the first administration of study drug, and must agree to use highly effective physician-approved contraception from Screening to 90 days following the last study drug administration 13.Male subjects must be surgically sterile or must agree to use highly effective physician approved contraception from Screening to 90 days following the last study drug administration 14.Ability to understand and willingness to sign an informed consent form prior to initi
Exclusion criteria: 1.Non-AL amyloidosis 2.NT-proBNP >8500 pg/mL 3.Meets the International Myeloma Working Group (IMWG) definition of multiple myeloma *Note that subjects who meet the IMWG definition of symptomatic multiple myeloma with signs and/or symptoms attributable only to associated amyloidosis are potentially eligible upon approval of the Sponsor. 4.Subject is eligible for and plans to undergo ASCT or organ transplant during the study 5.Symptomatic orthostatic hypotension that in the medical judgment of the Investigator would interfere with the subject's ability to safely receive treatment or complete study assessments 6.Myocardial infarction, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or ECG evidence of acute ischemia, within 6 months prior to the Month 1-Day 1 Visit 7.Severe valvular stenosis (e.g., aortic or mitral stenosis with a valve area <1.0 cm2) or severe congenital heart disease 8.ECG evidence of acute ischemia or active conduction system abnormalities with the exception of any of the following: -First degree AV-block -Second degree AV-block Type 1 (Mobitz Type 1 / Wenckebach type) -Right or left bundle branch block -Atrial fibrillation with a controlled ventricular rate (uncontrolled [>110 bpm] ventricular rate is not allowed [determined by an average of 3 beats in Lead II or 3 representative beats if Lead II is not representative of the overall ECG]) 9.Peripheral neuropathy assessed as National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade 2 with pain, Grade 3, or Grade 4 10.Subject is receiving oral or intravenous antibiotics, antifungals, or antivirals within 1 week of Month 1-Day 1 with the exception of prophylactic oral agents 11.Prior treatment with hematopoietic growth factors, transfusions of blood or blood products within 1 week of Month 1-Day 1 12.Prior radiotherapy within 4 weeks of Month 1-Day 1 13.Major surgery within 4 weeks of Month 1-Day 1 or planned major surgery during the study 14.Active malignancy with the exception of any of the following: -Adequately treated basal cell carcinoma, squamous cell carcinoma, or in situ cervical cancer -Adequately treated Stage I cancer from which the subject is currently in remission and has been in remission for 2 years -Low-risk prostate cancer with Gleason score <7 and prostate specific antigen <10 ng/mL -Any other cancer from which the subject has been disease-free for =2 years 15.History of severe allergy to any of the components of birtamimab such as histidine/L histidine hydrochloride monohydrate, trehalose dehydrate, or polysorbate 20 or history of Grade =3 infusion-related AEs or hypersensitivity to another monoclonal antibody, or known hypersensitivity to diphenhydramine (or an equivalent H1 antihistamine) or acetaminophen (or its equivalent, paracetamol) 16.Known or history of uncontrolled, active HIV, hepatitis B or hepatitis C, or SARS-CoV-2 infection 17.Prior treatment with plasma cell-directed chemotherapy, birtamimab, daratumumab, 11 1F4, anti-serum amyloid P antibody, doxycycline for amyloid, or other investigational treatment directed at amyloid 18.Treatment with another investigational agent within 30 days of Month 1-Day 1 19.Women who are pregnant or lactating 20.Any condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the Investigator, unacceptably increase the subject's risk by participating in the study 21.Subject
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
AL amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains.
Overproduction of misfolded light chains results in both soluble, aggregated forms of light chains and insoluble, fibrillar deposits of
abnormal AL protein (amyloid), in the tissues and organs. This can cause a range of symptoms and organ dysfunction including cardiac, renal, and
hepatic dysfunction, gastrointestinal involvement and neuropathy and macroglossia MedDRA version: 20.0
Level: PT
Classification code 10036673
Term: Primary amyloidosis
System Organ Class: 10021428 - Immune system disorders
|
Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
|
Intervention(s)
|
Product Name: Birtamimab Product Code: [Birtamimab] Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: BIRTAMIMAB CAS Number: 1608108-91-3 Current Sponsor code: birtamimab Other descriptive name: Humanized IgG1 kappa antiamyloid Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use
Product Name: paracetamolo Zentiva Italia Product Code: [NA] Pharmaceutical Form: Tablet INN or Proposed INN: PARACETAMOLO Current Sponsor code: NA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500-
Trade Name: Bortezomib Accord Product Name: Bortezomib Accord Product Code: [Bortezomib Accord] Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: BORTEZOMIB Current Sponsor code: NA Other descriptive name: Bortezomib D-mannitol Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 3500-
Product Name: Zirtec Product Code: [NA] Pharmaceutical Form: Tablet INN or Proposed INN: CETIRIZINA DICLORIDRATO Current Sponsor code: NA Other descriptive name: NA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10-
Product Name: Aciclin Product Code: [NA] Pharmaceutical Form: Tablet INN or Proposed INN: ACICLOVIR Current Sponsor code: NA Concentration unit: mg milligram(s) Concentration type: range Concentration number: 200-400
|
Primary Outcome(s)
|
Main Objective: To evaluate the efficacy of birtamimab plus standard of care compared to placebo plus standard of care when administered intravenously in Mayo Stage IV subjects with AL amyloidosis by assessing time to all-cause mortality.
|
Primary end point(s): Time to all-cause mortality
|
Secondary Objective: To evaluate birtamimab plus standard of care compared to placebo plus standard of care on the following: • Change from baseline to Month 9 in health-related quality of life using the Short Form-36 questionnaire Version 2 (SF-36v2) • Change from baseline to Month 9 in the 6-Minute Walk Test (6MWT) distance
|
Timepoint(s) of evaluation of this end point: -Interim Efficacy Analysis will be conducted when approximately 50% (or 24) of the events have occurred -Primary Analysis - for all-cause mortality, all deaths occurring after the first infusion of study drug (i.e., Study Day 1) through the study's last subject last visit will be included.
|
Secondary Outcome(s)
|
Timepoint(s) of evaluation of this end point: from baseline until Month 9
|
Secondary end point(s): •Change from baseline to Month 9 in the Physical Component Summary (PCS) score of the SF-36v2 •Change from baseline to Month 9 in the 6MWT distance (meters)
|
Secondary ID(s)
|
NCT04973137
|
146070
|
2021-000037-14-DK
|
NEOD001-301
|
Source(s) of Monetary Support
|
Prothena Biosciences Limited
|
Ethics review
|
Status: Approved
Approval date: 15/12/2021
Contact:
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|